N@N

Balaji Prasad Maintained (TEVA) at Buy with Increased Target to $15 on, Jan 29th, 2024

Balaji Prasad of Barclays, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Buy with Increased Target from $14 to $15 on, Jan 29th, 2024.

Balaji has made no other calls on TEVA in the last 4 months.

There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 1 agrees with Balaji's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• David Amsellem of "Piper Sandler" Upgraded from Sell to Hold and Increased Target to $12 on, Wednesday, January 3rd, 2024

These are the ratings of the 3 analyists that currently disagree with Balaji

---

• Glen Santangelo of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $14 on, Tuesday, January 23rd, 2024
• Rajesh Kumar of "HSBC" Initiated at Strong Buy and Held Target at $13 on, Monday, December 18th, 2023
• Ashwani Verma of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $13 on, Monday, November 27th, 2023

Contributing Sources

---